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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the benefits and harms of self management programmes for people with AS/Axial SpA.
B A C K G R O U N D
Description of the condition
Ankylosing spondylitis (AS) is a chronic systemic inflammatory
musculoskeletal condition belonging to a family of diseases known
as the spondyloarthropathies (Khan 2003). This condition is char-
acterised by inflammation of spinal joints and adjacent structures
that may lead to progressive and ascending bony fusion of the
spine (Davis 2005). The exact origin of AS is unknown, but it
is recognised that both environmental and genetic factors play
a role, and the condition is strongly associated with the HLA-
B27 gene (Khan 2003). The term ’Axial SpA’ has been used to
describe the condition since diagnosis was refined by the Assess-
ment of Spondyloarthritis International Society (ASAS) in 2009
(Rudwaleit 2009b). Axial SpA is a form of spondyloarthritis for
which the predominant symptom is chronic inflammatory back
pain, but radiographic sacroiliitis may or may not be present. The
new classification criteria extend the diagnosis to encompass non-
radiographic Axial SpA, beyond the Modified New York Crite-
ria used previously (Van der Linden 1984), by which diagnosis
depended upon x-ray changes at the sacroiliac joint. The depen-
dence on radiographic changes contributed to patients’ experienc-
ing long delays in diagnosis, with many cases remaining unrecog-
nised (Rudwaleit 2004). The mean prevalence of AS per 10,000 is
estimated at 23.8 in Europe, 16.7 in Asia, 31.9 in North America,
10.2 in Latin America and 7.4 in Africa (1.30 to 1.56million cases
in Europe; 4.63 to 4.98 million cases in Asia) (Dean 2014). Preva-
lence estimates based on New York or Modified New York criteria
were approximately double those based on clinical criteria. One
US study reported a prevalence rate of 70 cases per 10,000 while
using the new ASAS criteria (Strand 2013), which may indicate
the potential for higher prevalence rates, depending on themethod
of diagnosis applied. Prevalence is generally higher among males,
with rate estimates ranging from 1.2 to seven times higher than
in females (Dean 2014). However, results from a Canadian study
suggest that the proportion of females is rising, with male/female
ratios falling from 1.7:1 to 1.2:1 over a 15-year period (Haroon
2014).
Chronic symptoms, the unpredictability of flare, vulnerability to
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physical distress, the uncertain disease course and progressive im-
pairment of physical functioning represent a significant long-term
impact on lifestyle factors such as career, family and social life
(Barlow 2001;Doward 2003). AS/Axial SpA is responsible for sub-
stantial direct and indirect socioeconomic costs, including work
disability, which 20 years post diagnosis may be as high as 30%
compared with the general population (Boonen 2001; Boonen
2002; Sieper 2002). Consequently, the condition has a significant
impact on quality of life (Ward 1999; Haywood 2003). The phys-
ical and psychosocial impact of AS/Axial SpA is associated with
substantial personal and societal costs that rise substantially with
increasing functional limitations (Boonen 2006; Kobelt 2006;
Hamilton-West 2009). Patients with a non-radiographic diagno-
sis experience a similar burden of disease and impact on health-re-
lated quality of life as those with radiographically confirmed Axial
SpA (Rudwaleit 2009a; Kiltz 2012).
Description of the intervention
Strategies for managing AS aim to reduce symptoms of pain and
stiffness, improve and/or maintain function and mobility, prevent
disability, improve quality of life and prevent structural damage
(Maksymowych 2006). Treatment of AS has evolved from symp-
tomatic relief to modification of disease activity through use of
biological therapies such as anti-tumour necrosis factor (TNF),
which has led to reductions in morbidity and mortality (Scalapino
2003). Management of AS/Axial SpA involves a combination of
pharmacological and non-pharmacological interventions. Patient
education and physical exercise are the cornerstones of non-phar-
macological management.Non-steroidal anti-inflammatory drugs
(NSAIDs) are recommended as first-line drug treatment for pa-
tients with AS/Axial SpA with symptomatic inflammatory back
pain (Braun 2011). Anti-TNF therapy may reduce disease activity
in patients with highly active disease who have failed to respond
to NSAIDs (Davis 2005b; Braun 2008; van der Heijde 2009), but
it has not been shown to reduce radiographic progression (van der
Heijde 2008; van der Heijde 2008b; van der Heijde 2009b).
Self management for people with AS/Axial SpA focuses on two
key areas: medical management - such as taking medications, ac-
companied by a regimen of exercises, diet, etc.; and psychosocial
adaptation - such as coping with anger, fear and frustration, and
accommodating various new life roles in relation to jobs, family
and friends (Corbin 1988; McGowan 2005). Self management
has been defined as ’the individual patient ability and competence
regarding the management of symptoms, treatment, physical and
psychosocial consequences and the lifestyle changes inherent in
living with a chronic condition’ (Barlow 2000b). The core con-
cept in self management is realisation of self efficacy, that is, con-
fidence in oneself to carry out the required behaviour to acquire
the desired goal (Bandura 1997). Education in effective self man-
agement is focused on problem solving, decision making, using
resources and establishing good communication with healthcare
providers (Arnold 1995; Anderson 1996; Von Korff 1997; Lorig
2003a).
In the 1970s, Kate Lorig at Stanford University was the first to
develop a self management programme that was used for patients
with arthritis (Brady 2003). Since that time, this programme has
been applied in various chronic conditions, including osteoarthri-
tis and rheumatoid arthritis, with evidence of improvement in
self efficacy, pain, depression, disability, healthcare utilization and
costs (Lorig 1993; Barlow 2000a; Lorig 2003b; Chodosh 2005;
Lorig 2005; Lorig 2006; Osborne 2006; Elzen 2007). Most self
management programmes have been delivered face-to-face, but
now many can be delivered over the Internet (Lorig 2008).
How the intervention might work
Objectives of self management programmes include engaging in
activities such as exercise to promote health, build physiological
reserve and prevent adverse sequelae; empowering interactionwith
healthcare providers and adherence to recommended treatments
and techniques; and setting goals (Osborne 2004).
Why it is important to do this review
No cure for AS/Axial SpA is known, so the main goal of treatment
for individuals with this lifelong condition is to enable optimal
self management. Poor self management increases the burden of
disease on the individual and on healthcare resources; therefore
effective disease management is essential. The overall effectiveness
of self management programmes for AS/Axial SpA remains un-
clear. Two reviews have examined self management educational
programmes but have not specifically focused on people with AS/
Axial SpA (Foster 2007; Kroon 2014); one is limited to interven-
tions delivered by lay people (Foster 2007). Our review focuses
specifically on interventions for self management delivered by any
trained person for people with AS/Axial SpA.
O B J E C T I V E S
To assess the benefits and harms of self management programmes
for people with AS/Axial SpA.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We will include only randomised clinical trials (RCTs) and quasi-
randomised trials (defined as trials in which participants are allo-
cated to study groups according to, for example, date of birth or
alternate allocation) that fulfil the following criteria.
• Self management programmes versus control. Control
group defined as follows: no intervention, or specific
intervention (such as information or instructions on
medications, exercise, information booklets or social supports) or
self management programmes without a programme leader.
• Studies reporting results for pooled AS/Axial SpA
populations. When data are available, we will also report
populations separately.
We will include studies published in any language.
Types of participants
Inclusion criteria
Studies with participants over 18 years of age with a clinical diag-
nosis of AS as defined by the Modified New York criteria (Van der
Linden 1984), or with a diagnosis of Axial SpA as defined by the
ASAS classification criteria (Rudwaleit 2009b).
Exclusion criteria
Diagnostic criteria have not been met, or the diagnosis involves
uncertainty.
Types of interventions
Inclusion criteria
Self management programme has been designed for people with
AS or Axial/SpA.
Programme content must include at least one component from
each of the following: biological, psychological and social man-
agement; interventions must consist of disease information about
AS/Axial SpA, medication management, exercise, disease-related
problem solving, cognitive symptom management, management
of emotions, communication skills and use of community re-
sources (Holman 2004).
Participants should interact with a programme leader who is a
healthcare professional or a trained layperson.
Programmes may be delivered face-to-face or via the Internet, pro-
vided they meet the above criteria with direct or indirect trained
support provided, as described above.
Exclusion criteria
Non-randomised studies. Studies in which interventions focus
only on a specific component such as exercise, cognitive symptom
management or social support.
Types of outcome measures
Effects of self management may last for a few days or for many
months. We will therefore report short-term (up to six months)
and longer-term (longer than six months) follow-up separately.
We will measure mean improvement in score on the following
outcomes (unless otherwise stated).
Primary outcomes
• Pain, e.g. Medical Outcomes Study Pain Scale or Oswestry
Low Back Pain Disability Questionnaire.
• Self efficacy in symptom management/self management,
e.g. General Self-Efficacy Scale or Stanford Self-Efficacy Scale
(SSES).
• Positive and active engagement in life (including return to
work, fulfilling roles within the family).
• Disease activity, e.g. Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI).
• Physical function, e.g. Bath Ankylosing Spondylitis
Functional Index (BASFI).
• Number of withdrawals due to adverse events.
• Number of serious adverse events.
Secondary outcomes
• Patient’s global assessment of disease activity, e.g. Bath
Ankylosing Spondylitis Global assessment (BASG).
• Spinal mobility, e.g. Bath Ankylosing Spondylitis
Metrology Index (BASMI).
• Health-related quality of life, e.g. Ankylosing Spondylitis
Quality of Life (ASQoL), Evaluation of Ankylosing Spondylitis
Quality of Life (EASIQoL), Short Form (SF)-36, EuroQoL
Group Quality of Life Questionnaire (EQ5D), World Health
Organization Quality of Life (WHOQoL).
• Fulfilment of response criteria, e.g. proportion of
responders according to ASAS20 (improvement ≥ 20%),
ASAS40 (improvement ≥ 40%), etc.
• Depression, e.g. Hospital Anxiety and Depression Scale.
• Fatigue, e.g. Multidimensional Assessment of Fatigue Scale.
We will report primary outcomes in a ’Summary of findings’ table.
Search methods for identification of studies
See Cochrane Musculoskeletal Group (CMSG) methods used in
Reviews.
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Electronic searches
We will use the search strategy developed by the Cochrane Mus-
culoskeletal Group to search the following electronic databases for
primary studies.
• The Cochrane Central Register of Controlled Trials
(CENTRAL).
• MEDLINE (Ovid) 1946 to present.
• EMBASE (Ovid) 1947 to present.
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOHost) 1980 to present.
• PsycINFO (Ovid) 1806 to present.
• Physiotherapy Evidence Database (PEDro).
We will use the MEDLINE highly sensitive version of the RCT
filter from Chapter 6 of the Cochrane Handbook for Systematic
Reviews of Interventions (Lefebvre 2011).We will search for studies
published in any language at any time and in any format.
We will modify the Ovid MEDLINE search strategy (Appendix
1) to suit other bibliographic databases.
Searching other resources
We will search ’grey’ literature, such as reports and conference
proceedings, using the System for Information on Grey Litera-
ture in Europe (SIGLE). We will search www.Clinicaltrials.gov
and the World Health Organization International Clinical Trial
Registry Platform (ICTRP) (www.who.int/ictrp/en) to identify
trials in progress. We will contact experts in the fields of public
health, rheumatology, medicine and rehabilitation to request in-
formation on unpublished and ongoing trials of self management
programmes for AS.
We will also search the Database of Abstracts of Reviews of Effects
(DARE) via The Cochane Library to identify potentially relevant
reviews. We will screen the reference lists of reviews and primary
studies to identify additional studies for inclusion in this review.
Data collection and analysis
Selection of studies
Two review authors (EM, JM) will independently assess the titles
and abstracts of all retrieved trials. The same review authors will
then examine the full text of papers identified as relevant to assess
studies for inclusion in this review. We will resolve disagreements
about eligibility and inclusion by consulting with a third review
author (SS).
Data extraction and management
SS and JM will independently read and extract data from in-
cluded studies using a form based on predefined outcome mea-
sures. We will contact study authors to request information on
missing data or further information about the trial. We will sys-
tematically record information on study design, participants, in-
terventions, outcomes, methods, results and study withdrawals in
’Characteristics of included studies’ tables.
We will resolve disagreements by consulting with a third review
author (PM).
When possible, review authors will report with a consistent direc-
tion of effect (i.e. favourable outcome to left of line of no effect).
Assessment of risk of bias in included studies
SS and JM will independently assess each included study for risk
of bias using the criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will rate
risk of bias as high, low or unclear across the domains below. We
will resolve disagreements by consulting with a third review author
and will tabulate results in a ’Risk of bias’ table.
Random sequence generation
• Low risk of bias: adequate sequence generation (e.g.
random number tables, coin toss, drawing lots, dice throw).
• High risk of bias: inadequate sequence generation using a
non-random method of allocation (e.g. date of birth, hospital
admission date, clinic number).
• Unclear risk of bias: information on sequence generation
not given or unclear.
Allocation concealment
• Low risk of bias: adequate concealment (e.g. central
allocation method such as telephone or Web-based
randomisation, sealed opaque envelopes).
• High risk of bias: inadequate concealment of allocation
(e.g. open list of numbers, envelopes without concealed contents,
dates of birth).
• Unclear risk of bias: information on allocation of
randomisation not given or unclear.
Blinding of participants and personnel
• Low risk of bias: adequate when study participants and
personnel are blinded to allocated interventions, or when review
authors judge that study outcomes will not be influenced by lack
of blinding.
• High risk of bias: inadequate when study outcomes are
likely to be influenced by lack of or incomplete blinding.
• Unclear risk of bias: information on blinding of
participants and personnel not given or unclear.
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Blinding of outcome assessment
• Low risk of bias: adequate when study participants and
personnel are blinded to outcome assessment, or when review
authors judge that outcome measures will not be influenced by
lack of blinding.
• High risk of bias: inadequate when measurement of
outcomes is not blinded and may be influenced by lack of
blinding.
• Unclear risk of bias: information on blinding of outcome
assessment not given or unclear.
Incomplete outcome data
• Low risk of bias: adequate (e.g. no missing data, missing
data unrelated to true outcome (e.g. survival data), balanced
across study groups, reasons for missing data similar across
groups).
• High risk of bias: inadequate (e.g. missing data may be
related to true outcome (missing not at random), reasons for
missing data or missing proportions differ between groups,
imputation is inappropriate (e.g. high proportion of data
imputed using last observation carried forward)).
• Unclear risk of bias: information on incomplete outcome
data not given or unclear.
Selective reporting
• Low risk of bias: adequate (e.g. clear that all prespecified or
expected study outcomes have been reported consistently).
• High risk of bias: inadequate (e.g. not all prespecified
outcomes reported, primary outcomes reported that were not
prespecified, outcomes reported using methods not prespecified).
• Unclear risk of bias: information on outcome reporting not
given or unclear.
Other bias
• Low risk of bias: adequate when no other sources of bias are
identified.
• High risk of bias: inadequate when other important sources
of bias are identified, such as inappropriate study design.
• Unclear risk of bias: insufficient information for evaluation
of risk of other bias.
Measures of treatment effect
Binary data
For binary data, risk ratio (RR), Peto odds ratio (for rare events
< 10%) and 95% confidence intervals (CIs) will be estimated
according to intention-to-treat principles. For pooled data, the
fixed-effect model will be preferred, but the random-effects model
will be used when heterogeneity is present.
Continuous data
Skewed data: Continuous data on clinical and social outcomes of-
ten are not normally distributed. To avoid the pitfall of applying
parametric tests to non-parametric data, we will apply the follow-
ing standards to all data before inclusion: (1) Standard deviations
and means must be reported in the paper or must be obtainable
from study authors; (2) when a scale starts from a finite number
(such as zero), the standard deviation, when multiplied by two,
must be less than themean (as otherwise, themean is unlikely to be
an appropriate measure of the centre of the distributions) (Altman
1996). Endpoint scores on scales often have finite start and end
points, and this rule can be applied to them. When sample sizes
are thought to be too small, we will consider non-parametric and
more exact statistical procedures. We will seek assistance from the
CMSG statistician, should the need arise.
Summary statistic: For continuously distributed outcomes, wewill
calculate the mean difference (WMD) when the same scale is
used in a similar manner across studies; otherwise, we will use
the standardised mean difference (SMD). We will use a fixed-
effect model in the first instance but the random-effects model to
investigate the sensitivity of results to choice of statistical method.
Unit of analysis issues
Cross-over trials
We will use only data from the first pre-cross-over phase to min-
imise potential bias from carry-over effects.
Cluster trials
We will analyse these in accordance with methods described in
Section 16.3 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011), using average cluster size and an
estimate of the intraclass correlation co-efficient (ICC) to adjust
sample sizes to the ’effective sample size’. When an estimate of the
ICC is not available from trial information, we will use an esti-
mate from a similar trial or from a trial with a similar population.
We will combine single RCTs with cluster RCTs if we consider
designs and interventions sufficiently similar, and if the effect of
the intervention is not likely to be influenced by the method of
randomisation.
Multiple-arm trials
For trials with more than two arms, we will describe all study
groups in the ’Characteristics of included studies’ table, but we
will include in the analysis only intervention groups that meet our
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review criteria. When the variance of the difference between in-
tervention and comparator is not reported, we will calculate this
from the variances of all trial arms. When a study includes multi-
ple relevant treatment arms, we will combine groups to perform a
single pairwise comparison (Higgins 2011). If this prevents identi-
fication of potential heterogeneity, we will analyse each group sep-
arately against a common control group. However, to ensure that
a common control group is not included multiple times in a meta-
analysis that includes several interventions from the same trial, we
will proportionately reduce control group data (Higgins 2011).
For example, in a study with two interventions and a single con-
trol group, we will halve the numbers of participants and events in
the control group. When studies report only differences between
treatment groups, as opposed to mean effects for each group, we
will analyse data using the generic inverse variance function.
Dealing with missing data
We will contact all authors of included studies to request unre-
ported data such as missing outcomes, missing data, means or
SDs. We will note differential dropout between study groups and
reasons for withdrawal. When a particular outcome includes sub-
stantial loss to follow-up (50%), we will report this in the text
and will mark the data with an asterisk. We will note differential
missing data and reasons for missing data, when reported. We will
use intention-to-treat (ITT) principles for data analysis and will
not impute missing data. When studies report per-protocol data
(i.e. only those who completed the study), we will contact study
authors to request unreported data on all study participants. We
will describe missing data in the ’Risk of bias’ table and will discuss
in the text the influence of missing data on study outcomes. If
trials are sufficient, we will use sensitivity analyses to determine
the resistance of our results to the effects of missing data.
Assessment of heterogeneity
We will assess heterogeneity by using the Chi2 test in conjunction
with the I2 statistic. We will set significance for the Chi2 test at
P value ≤ 0.10 because of the low power of this test (Higgins
2011). We will keep the cut point for I2 at 50%. When significant
heterogeneity is present, we will attempt to explain differences
based on clinical characteristics of included studies.
Assessment of reporting biases
Wewill compare data from published and unpublished studies as a
direct test of publication bias. If we identify a sufficient number of
studies (approximately ≥ 10), we will explore potential reporting
biases and small study effects by using Egger’s method (Egger
1997) to test for asymmetry in funnel plots.
Data synthesis
We will included in meta-analyses studies in which study designs,
interventions and outcomes are similar. When we identify sub-
stantial heterogeneity, we will report outcomes narratively in the
text. It is likely that studies on self management programmes for
AS will vary by population, design and outcomes, so we will use
a random-effects model for pooled analyses. However, when few
studies are found (as may be the case with this review) or when ef-
fects of the intervention are not randomly distributed across stud-
ies (e.g. with publication bias), random-effects model estimates
may be unreliable. To resolve uncertainty over model choice, we
will (1) pool data using meta-analyses only when studies appear
sufficiently similar, and (2) compare pooled data estimates from
both random-effects and fixed-effect models, while reporting both
in the text. We will report the mean effect estimate and the con-
fidence interval (CI) around the estimate for both models, not-
ing that the CI for the random-effects model is not an estimate
of heterogeneity. For dichotomous outcomes, we will sum sample
sizes and events across groups, and for continuous outcomes, we
will combine means and standard deviations using the formula
described in Chapter 7 of the Cochrane Handbook for Systematic
Reviews of Interventions (Section 7.7.3.8 Higgins 2011). We will
synthesise and report dichotomous and continuous data separately
for a given outcome, should the need arise. When both end-of-
study differences and changes from baseline are reported, we will
analyse these separately. We will perform these analyses using Re-
view Manager 5.2.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses
When sample sizes of intervention groups permit, we will conduct
subgroup analyses of the following.
• Disease classification: AS versus Axial SpA.
• Intervention type: We will ask an independent group of
researchers to classify the interventions while remaining blinded
to treatment effects.
Investigation of heterogeneity
If numbers of studies are sufficient, we will manage potential
sources of heterogeneity as follows.
• Check data integrity, including measures of effect and units
of analysis.
• Explore the impact of subgroups (e.g. small vs large studies).
• Exclude outliers when the reason for exclusion is clear. We
will inspect the graph and will iteratively remove outlying studies
to determine whether homogeneity is restored.
We will fully discuss and report our decisions in the review.
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Sensitivity analysis
We will perform sensitivity analysis by excluding studies with the
following.
• High I2 (≥ 50%).
• Inadequate allocation concealment.
• Low attrition rates.
We will compare results with and without data from unpublished
studies.
’Summary of findings’ table
We will report primary outcomes of the review in a ’Summary of
findings’ table (self efficacy, positive and active engagement in life,
disease activity, global well-being, physical function, health-related
quality of life and adverse events). The ’Summary of findings’
table will rate evidence related to each outcome according to the
GRADE (Grades of Recommendation, Assessment, Development
and Evaluation) criteria (Schunemann 2011).
We will express pooled SMDs as mean differences by multiply-
ing each SMD by a relevant trial control group baseline standard
deviation. In the comments column, we will report the absolute
percentage change and the relative percentage change, and for out-
comes with statistically significant differences between groups, we
will also report the number needed to treat for an additional ben-
eficial outcome (NNTB).
For dichotomous outcomes, we will calculate the following: abso-
lute risk difference expressed as a percentage; relative percentage
change (risk ratio -1) expressed as a percentage; NNTB from the
control group event rate and risk ratio obtained with the Visual
Rx NNTB calculator (Cates 2013).
For continuous outcomes, wewill calculate the following: absolute
risk difference (mean difference divided by the scale) expressed
as a percentage; and relative difference (change or mean differ-
ence divided by relevant control group baseline mean). We will
use theWells calculator to obtain the NNTB for continuous mea-
sures (available at theCMSGEditorial office; http://musculoskele-
tal.cochrane.org/).
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A P P E N D I C E S
Appendix 1. Search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
--------------------------------------------------------------------------------
1 Spondylitis, Ankylosing/ (11620)
2 Spondylarthritis/ (815)
3 (axial adj2 spondylarthritis).tw. (16)
4 (axial adj2 spa).tw. (151)
5 (ankylos$ or spondyl$).tw. (30174)
6 (bekhterev$ or bechterew$).tw. (665)
7 (Marie adj struempell$).tw. (6)
8 or/1-7 (33478)
9 exp Self Care/ (39952)
10 ((self or symptom$) adj (care or help or manag$ or directed or monitor$ or efficacy or admin$)).tw. (72002)
11 Patient Education as Topic/ (69613)
12 ((health or patient$) adj2 (educat$ or information)).tw. (79427)
13 exp Consumer Participation/ (31753)
14 ((patient$ or consumer$) adj part$).tw. (16172)
15 “power (psychology)”/ (9933)
16 empower$.tw. (12584)
17 Holistic Health/ (6985)
18 (holistic or wholistic).tw. (11875)
19 exp Rehabilitation/ (147043)
20 rehab$.tw. (107810)
21 “Activities of Daily Living”/ (49414)
22 (activit$ adj2 daily adj living).tw. (16033)
23 social support/ (50659)
24 (social adj (support or network$)).tw. (27981)
25 (support adj system$).tw. (8741)
26 exp Adaptation, Psychological/ (101323)
27 (psychologic$ adj (adjust$ or adapt$)).tw. (2473)
28 (cope or copes or coping).tw. (50737)
29 exp Behavior Therapy/ (51924)
30 (adapt$ adj behav$).tw. (3007)
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31 (behav$ adj (therap$ or intervention$)).tw. (17332)
32 or/9-31 (691720)
33 8 and 32 (1269)
34 randomized controlled trial.pt. (370699)
35 controlled clinical trial.pt. (88158)
36 randomized.ab. (290757)
37 placebo.ab. (152961)
38 clinical trials as topic.sh. (169353)
39 randomly.ab. (210816)
40 trial.ti. (125012)
41 or/34-40 (896351)
42 exp animals/ not humans.sh. (3923244)
43 41 not 42 (827154)
44 33 and 43 (138)
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